NKTR Nektar Therapeutics

NASDAQ
$34.42

Nektar Therapeutics (NKTR) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $2.51 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -6.5% since its last earnings release on November 12, 2026.

Nektar Therapeutics Beat Consensus Estimates
Thursday, November 12, 2026 · 4:15 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 11
Thursday · 4:15 PM ET
Earnings Whisper
-
vs ($2.51)
Rev est $9.11M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $35.97

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Nektar Therapeutics

Nektar Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company develops a pipeline of drug candidates that utilizes its PEGylation and polymer conjugate technology platforms that are designed to develop molecular entities.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.